Case 36-2009: A 23-year-old man with cough, hoarseness, and abnormalities on chest imaging

New England Journal of Medicine

Volumn 361, Issue 21, 2009, Pages 2080-2087

  Choy, Edwin ^a,b   Digumarthy, Subba R ^a,b   Koplin, Stephanie A ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; VINCRISTINE;

ADULT; ANAMNESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DIFFERENTIAL DIAGNOSIS; EWING SARCOMA; HISTOPATHOLOGY; HOARSENESS; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY; BONE TUMOR; CLINICAL OBSERVATION; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSIS; FATALITY; ILIAC BONE; LUNG TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MEDIASTINUM TUMOR; METASTASIS; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING;

BONE NEOPLASMS; COUGH; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HOARSENESS; HUMANS; ILIUM; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDIASTINAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOGRAPHY, THORACIC; SARCOMA, EWING'S; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 70949108218     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0907804     Document Type: Article

References (21)

1. Dominguez Malagón H, Pérez Montiel D. Mediastinal germ cell tumors. Semin Diagn Pathol 2005;22:230-240
2. Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988;32:229-238
3. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245-1251
4. Zoubek A, Pfleiderer C, Salzer-Kuntschik M, et al. Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer 1994;70:908-913 (Pubitemid 24331085)
5. de Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-792 (Pubitemid 30658577)
6. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-1255 [Erratum, J Clin Oncol 1998;16:2895.]
7. de Alava E, Panizo A, Antonescu CR, et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000;156:849-855 (Pubitemid 30626943)
8. Honoki K, Stojanovski E, McEvoy M, et al. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 2007;110:1351-1360 (Pubitemid 47435609)
9. Wei G, Antonescu CR, de Alava E, et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000;89:793-799 (Pubitemid 30658578)
10. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999;79:1185-1189 (Pubitemid 29087896)
11. Caudill JS, Arndt CA. Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev 2007;18:62-78.
12. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114 (Pubitemid 30677091)
13. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-418
14. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352
15. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
16. Juergens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006;47:22-29
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-928 [Erratum, Nat Rev Cancer 2009;9:224.]
18. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997;272:30822-30827 (Pubitemid 27527522)
19. Benjamin RS, Gore L, Dias C, et al. Activity of R1507, a fully humanized monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist, in patients with Ewing's sarcoma noted in a phase I study. Seattle: Connective Tissue Oncology Society, 2007. abstract.
20. Olmos D, Okuno S, Schuetze SM, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. In: Program and abstracts of the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, May 30-June 3, 2008. abstract.
21. NCI clinical trials search results for treatment trials on soft tissue sarcoma. Bethesda, MD: National Cancer Institute, 2009. (Accessed October 23, 2009, at http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid=5994605.)